Apellis Pharmaceuticals Inc
NASDAQ:APLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
US |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IST:SNGYO.E
|
TR |
|
Swatch Group AG
OTC:SWGAY
|
CH |
|
F
|
Firm Capital Apartment Real Estate Investment Trust
XTSX:FCA.U
|
CA |
|
T
|
TCL Technology Group Corp
SZSE:000100
|
CN |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
M
|
Minmetals Capital Co Ltd
SSE:600390
|
CN |
|
Tech Mahindra Ltd
NSE:TECHM
|
IN |
Apellis Pharmaceuticals Inc
In the realm of biotechnology, Apellis Pharmaceuticals Inc. has carved out a niche by pioneering therapies that target the complement system, an integral part of the immune response. Founded in 2009, the company quickly honed in on the inhibition of C3, a protein central to the activation of the complement cascade, which can drive various diseases when dysregulated. Through its proprietary platform, Apellis has developed novel therapeutic candidates that aim to modulate the immune system from an entirely fresh angle. The company focuses on addressing serious medical conditions that currently have limited treatment options, such as age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH), by employing targeted therapies to reduce inflammation and improve patient outcomes.
Apellis’s business strategy revolves around a model that not only aims to bring innovative treatments to market but also to establish partnerships that broaden the reach of its technology. The company's flagship drug, Empaveli, received FDA approval for PNH in 2021 and underscores its potential to capture larger market segments within rare disease treatment areas. By investing heavily in research and development, Apellis seeks to expand its pipeline while also collaborating with other firms to enhance its capabilities and share the risks and rewards associated with drug development. Revenue is generated primarily through sales of its approved therapies, as well as milestone payments and royalties from partnerships, setting Apellis on a path poised for growth if it continues to advance its clinical programs successfully.
In the realm of biotechnology, Apellis Pharmaceuticals Inc. has carved out a niche by pioneering therapies that target the complement system, an integral part of the immune response. Founded in 2009, the company quickly honed in on the inhibition of C3, a protein central to the activation of the complement cascade, which can drive various diseases when dysregulated. Through its proprietary platform, Apellis has developed novel therapeutic candidates that aim to modulate the immune system from an entirely fresh angle. The company focuses on addressing serious medical conditions that currently have limited treatment options, such as age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH), by employing targeted therapies to reduce inflammation and improve patient outcomes.
Apellis’s business strategy revolves around a model that not only aims to bring innovative treatments to market but also to establish partnerships that broaden the reach of its technology. The company's flagship drug, Empaveli, received FDA approval for PNH in 2021 and underscores its potential to capture larger market segments within rare disease treatment areas. By investing heavily in research and development, Apellis seeks to expand its pipeline while also collaborating with other firms to enhance its capabilities and share the risks and rewards associated with drug development. Revenue is generated primarily through sales of its approved therapies, as well as milestone payments and royalties from partnerships, setting Apellis on a path poised for growth if it continues to advance its clinical programs successfully.
Revenue: Apellis reported Q4 2025 revenue of $200 million and full-year 2025 revenue of $1 billion, which included a onetime $275 million payment from the Sobi royalty repurchase agreement.
SYFOVRE Performance: SYFOVRE net product revenue was $155 million in Q4 and $587 million for full-year 2025, with steady growth in total injections but modestly lower annual revenue due to increased free goods utilization.
EMPAVELI Launch: EMPAVELI reached over 5% market penetration after its first full quarter for C3G and primary IC-MPGN, outpacing other rare nephrology launches and receiving strong physician feedback.
Guidance & Outlook: SYFOVRE is expected to remain a stable revenue stream in 2026, with a modest cadence to growth; EMPAVELI is on track for steady growth toward potential blockbuster status.
Innovation Pipeline: Apellis is advancing pivotal trials for EMPAVELI in new kidney indications and progressing a prefilled syringe and AI-enabled OCT-F for SYFOVRE to support future growth.
Financial Stability: The company ended 2025 with $466 million in cash and expects sufficient resources to fund the business to profitability.
Operating Expenses: Operating expenses were $251 million in Q4, up from $239 million a year ago, and are expected to be modestly higher in 2026 due to investment in pivotal trials.
